Labcorp presents 2026 guidance and 2029 growth targets

Labcorp Holdings (NYSE: LH ) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. • Labcorp Holdings stock is feeling bearish pressure. What’s behind LH decline?

Reaffirming Financial Targets The company validated its full-year 2026 financial guidance. 01. 707 billion estimate. 30 billion.

Long-Term Growth Projections Looking ahead to 2029, the diagnostic testing maker provided an optimistic financial outlook. Management targets a compound annual revenue growth rate of 5% to 8%. 5%. By the end of 2029, the firm aims to expand its adjusted operating margin by 75 to 150 basis points.

Compound annual free cash flow growth should mirror the adjusted earnings growth over this period. Read Also: Labcorp Advances As AI Investments, Core Businesses Drive Growth Strategic Focus Areas To achieve these financial milestones, the health care giant established four core strategic priorities. First, the company plans to spearhead specialty testing by driving innovation in oncology, neurology, autoimmune diseases, and women’s health. Second, management wants to solidify the firm’s position as a preferred partner for health systems and pharmaceutical companies by utilizing distinct operational and scientific capabilities.

Third, the enterprise will push personalized health solutions forward, deploying scientific insights to guide therapy development and selection. Finally, advanced technology will shape the organization’s future operations. The firm plans to integrate artificial intelligence and robotics to scale its tailored health care experiences and maintain industry leadership. 12 at the time of publication on Thursday, according to Pro data.

Image via Shutterstock Read Also: Goldman Sachs Increases COIN Target to $219 on 'Everything Exchange' Push